Pliant Therapeutics Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Bernard Coulie

Chief Executive Officer (CEO)

US$5.2m

Compensación total

Porcentaje del salario del CEO	10.7%
Permanencia del CEO	7.2yrs
Participación del CEO	0.9%
Permanencia media de la dirección	7.1yrs
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bernard Coulie en comparación con los beneficios de Pliant Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2022	n/a	n/a	-US$123m
Sep 30 2022	n/a	n/a	-US$113m
Jun 30 2022	n/a	n/a	-US$109m
Mar 31 2022	n/a	n/a	-US$103m
Dec 31 2021	US$5m	US$556k	-US$97m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$75m
Dec 31 2020	US$2m	US$499k	-US$42m
Sep 30 2020	n/a	n/a	US$18m
Jun 30 2020	n/a	n/a	US$19m
Mar 31 2020	n/a	n/a	US$20m
Dec 31 2019	US$2m	US$428k	-US$7m

Compensación vs. Mercado: La compensación total de Bernard($USD5.19M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.62M).

Compensación vs. Ingresos: La compensación de Bernard ha aumentado mientras la empresa no es rentable.

CEO

Bernard Coulie (56 yo)

7.2yrs

Permanencia

US$5,190,781

Compensación

Dr. Bernard Coulie, Ph. D, M. D., M. B.A., serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairman since November 2022. He serves as President a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Bernard Coulie	President	no data	US$5.19m	0.91% $ 13.8m
Keith Cummings	Chief Financial Officer	4.3yrs	US$1.88m	0.16% $ 2.4m
Mike Ouimette	General Counsel & Corporate Secretary	2.5yrs	US$805.04k	0.020% $ 302.3k
Johannes Hull	Chief Business Officer	7.1yrs	US$1.65m	0.30% $ 4.6m
Éric Lefebvre	Chief Medical Officer	4.9yrs	US$1.97m	sin datos
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	sin datos	sin datos
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	sin datos	sin datos
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	sin datos	sin datos
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	sin datos	sin datos
Craig Muir	Interim Chief Technology Officer	no data	sin datos	sin datos
Christopher Keenan	Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Lily Cheung	Chief Human Resources Officer	less than a year	sin datos	sin datos

7.1yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 9PT es experimentado (7.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bernard Coulie	President	7.2yrs	US$5.19m	0.91% $ 13.8m
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Gayle Crowell	Independent Director	3.3yrs	US$287.91k	0% $ 0
Brian Metcalf	Member of Scientific Advisory Board	no data	sin datos	sin datos
Suzanne Bruhn	Independent Director	6.8yrs	US$288.29k	0.059% $ 899.3k
John Curnutte	Independent Director	5.7yrs	US$286.41k	0.049% $ 750.6k
Hoyoung Huh	Independent Chairman	5.3yrs	US$308.41k	0% $ 0
Smital Shah	Independent Director	4.1yrs	US$288.41k	0% $ 0
Bill Greenlee	Member of Scientific Advisory Board	no data	sin datos	sin datos

5.5yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 9PT se considera experimentada (5.5 años de antigüedad promedio).

Pliant Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Insufficient new directors

Recent updates

Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

Insufficient new directors

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings released: US$0.65 loss per share (vs US$0.75 loss in 3Q 2021)

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.64 loss in 2Q 2021)

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.64 loss in 1Q 2021)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers

Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Highlights Recent Developments for Lead Program Pln-74809 and Expected 2022 Milestones

Third quarter 2021 earnings released: US$0.75 loss per share (vs US$0.47 loss in 3Q 2020)

Pliant Therapeutics, Inc. Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.64 loss per share

Pliant Therapeutics, Inc. Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €28.60

Investor sentiment improved over the past week

New 90-day high: €26.40

Pliant Therapeutics, Inc. Announces Appointment of David Pyott to Board of Directors

Investor sentiment improved over the past week

New 90-day high: €24.21

Pliant Therapeutics Appoints Mike Ouimette as General Counsel and Corporate Secretary

New 90-day low: €19.00

Pliant Therapeutics, Inc. announced that it expects to receive $45 million in funding

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad